首页 > 最新文献

Journal of Clinical and Translational Endocrinology: Case Reports最新文献

英文 中文
Massive tissue deposition of cholesterol leading to multi-organ failure in cholestatic hypercholesterolemia 胆固醇淤积性高胆固醇血症导致多器官功能衰竭
Q4 Medicine Pub Date : 2025-08-21 DOI: 10.1016/j.jecr.2025.100199
Daniel R. Barros , Brian G. Ballios , Yogesh Patodia , Shaun Singer , Cheryl F. Rosen , Michael A. Seidman , Robert A. Hegele , Gary F. Lewis
Cholestasis-induced severe hypercholesteremia can result in various complications, including the development of xanthomas and concern that marked hypercholesterolemia may accelerate atherosclerosis. However, deposition of lipids and cholesterol in organs beyond the skin and tendons, to the extent that they induce organ dysfunction or organ failure, has not previously been reported. Here we present two cases of marked hypercholesterolemia resulting from hepatobiliary dysfunction and cholestasis. In one of the two individuals (patient 1) who presented to us at a later stage of disease progression than patient 2, massive cholesterol tissue deposition in the retina, myocardium and kidney resulted in profound vision loss and ultimately fatal cardiorenal failure, whereas the second individual (patient 2) was noted to have retinal cholesterol deposition with minimal vision loss but extensive, pruritic and painful, tuberoeruptive xanthomas. Both patients were placed on weekly or biweekly plasmapheresis to prevent further disease progression, which successfully lowered cholesterol from 62.2 to 6.92 mmol/L in patient 1 and 18.4 to 5.88 mmol/L in patient 2, respectively. Unfortunately, the massive tissue lipid deposition in patient 1 proved to be beyond recuperation for plasma exchange therapy. In contrast, one year of biweekly plasmapheresis in patient 2 yielded marked resolution of xanthomas and halted progression of retinal cholesterol deposition and vision loss. These cases highlight the importance of thorough, systemic examination in patients with severe hypercholesterolemia secondary to cholestatic liver disease and attention to the potential devastating impact of massive cholesterol tissue-deposition, beyond atherosclerosis, which can be ameliorated if detected early by frequent plasma exchange.
胆汁淤积引起的严重高胆固醇血症可导致各种并发症,包括黄疸的发展和对明显的高胆固醇血症可能加速动脉粥样硬化的担忧。然而,脂质和胆固醇在皮肤和肌腱以外的器官中沉积,并在一定程度上引起器官功能障碍或器官衰竭,以前没有报道过。在此,我们报告两例由肝胆功能障碍和胆汁淤积引起的明显高胆固醇血症。两名患者中,有一名患者(患者1)病情进展比患者2晚,在视网膜、心肌和肾脏中出现大量胆固醇组织沉积,导致严重视力丧失,最终导致致命的心肾衰竭,而另一名患者(患者2)出现视网膜胆固醇沉积,伴有轻微视力丧失,但出现广泛、瘙痒和疼痛的结节性发疹性黄瘤。两名患者均接受每周一次或两周一次的血浆置换,以防止疾病进一步进展,患者1成功地将胆固醇从62.2降至6.92 mmol/L,患者2成功地将胆固醇从18.4降至5.88 mmol/L。不幸的是,患者1的大量组织脂质沉积被证明无法通过血浆交换治疗恢复。相比之下,患者2进行为期一年的双周血浆置换治疗后,黄斑瘤明显消退,视网膜胆固醇沉积和视力丧失的进展得以停止。这些病例强调了对胆汁淤积性肝病继发的严重高胆固醇血症患者进行全面、系统检查的重要性,并强调了大量胆固醇组织沉积的潜在破坏性影响,而不仅仅是动脉粥样硬化,如果通过频繁的血浆交换及早发现,这种影响可以得到改善。
{"title":"Massive tissue deposition of cholesterol leading to multi-organ failure in cholestatic hypercholesterolemia","authors":"Daniel R. Barros ,&nbsp;Brian G. Ballios ,&nbsp;Yogesh Patodia ,&nbsp;Shaun Singer ,&nbsp;Cheryl F. Rosen ,&nbsp;Michael A. Seidman ,&nbsp;Robert A. Hegele ,&nbsp;Gary F. Lewis","doi":"10.1016/j.jecr.2025.100199","DOIUrl":"10.1016/j.jecr.2025.100199","url":null,"abstract":"<div><div>Cholestasis-induced severe hypercholesteremia can result in various complications, including the development of xanthomas and concern that marked hypercholesterolemia may accelerate atherosclerosis. However, deposition of lipids and cholesterol in organs beyond the skin and tendons, to the extent that they induce organ dysfunction or organ failure, has not previously been reported. Here we present two cases of marked hypercholesterolemia resulting from hepatobiliary dysfunction and cholestasis. In one of the two individuals (patient 1) who presented to us at a later stage of disease progression than patient 2, massive cholesterol tissue deposition in the retina, myocardium and kidney resulted in profound vision loss and ultimately fatal cardiorenal failure, whereas the second individual (patient 2) was noted to have retinal cholesterol deposition with minimal vision loss but extensive, pruritic and painful, tuberoeruptive xanthomas. Both patients were placed on weekly or biweekly plasmapheresis to prevent further disease progression, which successfully lowered cholesterol from 62.2 to 6.92 mmol/L in patient 1 and 18.4 to 5.88 mmol/L in patient 2, respectively. Unfortunately, the massive tissue lipid deposition in patient 1 proved to be beyond recuperation for plasma exchange therapy. In contrast, one year of biweekly plasmapheresis in patient 2 yielded marked resolution of xanthomas and halted progression of retinal cholesterol deposition and vision loss. These cases highlight the importance of thorough, systemic examination in patients with severe hypercholesterolemia secondary to cholestatic liver disease and attention to the potential devastating impact of massive cholesterol tissue-deposition, beyond atherosclerosis, which can be ameliorated if detected early by frequent plasma exchange.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"37 ","pages":"Article 100199"},"PeriodicalIF":0.0,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144893425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Two brothers with late onset Wolfram syndrome 兄弟俩都有晚发性Wolfram综合症
Q4 Medicine Pub Date : 2025-08-05 DOI: 10.1016/j.jecr.2025.100197
Lodi CW. Roksnoer , Virginie JM. Verhoeven , Femke AT. de Vries , Mandy van Hoek
Wolfram syndrome (OMIM #222300) is a rare cause of diabetes mellitus. Mutations in the WFS1 (Wolfram Syndrome-1) gene lead to diabetes mellitus, as well as deafness, neurological symptoms, urological and endocrinological disorders. We describe two brothers of Ashkenazi Jewish ancestry, with mild late-onset Wolfram syndrome. Both brothers were diagnosed with diabetes mellitus in their mid-twenties, and both had optic atrophy. The older brother had minor ataxia, the younger brother did not have any neurological symptoms. AVP deficiency (formerly known as diabetes insipidus) was excluded in the older brother. The younger brother was using desmopressin because of nocturia. There were no other signs of endocrinological or urological problems in both patients. Auto-immune diabetes mellitus, MODY and MIDD were excluded. Both brothers were found to be homozygous for the pathogenic variant c.1672C > T p. Arg558Cys in exon 8 of the WFS1 gene. This is a founder mutation in the Ashkenazi Jewish population. Their parents were not consanguineous. This mutation was only recently found to cause a milder phenotype than classical Wolfram syndrome due to less defective protein function.
Wolfram综合征(omim# 222300)是一种罕见的糖尿病病因。WFS1 (Wolfram Syndrome-1)基因突变可导致糖尿病、耳聋、神经系统症状、泌尿系统和内分泌系统疾病。我们描述了德系犹太人血统的两个兄弟,患有轻度迟发性Wolfram综合征。两兄弟都在25岁左右被诊断出患有糖尿病,而且都有视神经萎缩。哥哥有轻微共济失调,弟弟没有任何神经系统症状。AVP缺乏(以前称为尿崩症)在哥哥中被排除。弟弟因为夜尿症正在使用去氨加压素。两名患者均无其他内分泌或泌尿系统问题的迹象。排除自身免疫性糖尿病、MODY和MIDD。两兄弟均为致病变异c.1672C >的纯合子;WFS1基因外显子8中的Arg558Cys。这是德系犹太人群体的创始突变。他们的父母没有血缘关系。由于蛋白质功能缺陷较少,这种突变最近才被发现引起比经典Wolfram综合征更温和的表型。
{"title":"Two brothers with late onset Wolfram syndrome","authors":"Lodi CW. Roksnoer ,&nbsp;Virginie JM. Verhoeven ,&nbsp;Femke AT. de Vries ,&nbsp;Mandy van Hoek","doi":"10.1016/j.jecr.2025.100197","DOIUrl":"10.1016/j.jecr.2025.100197","url":null,"abstract":"<div><div>Wolfram syndrome (OMIM #<span><span>222300</span><svg><path></path></svg></span>) is a rare cause of diabetes mellitus. Mutations in the WFS1 (Wolfram Syndrome-1) gene lead to diabetes mellitus, as well as deafness, neurological symptoms, urological and endocrinological disorders. We describe two brothers of Ashkenazi Jewish ancestry, with mild late-onset Wolfram syndrome. Both brothers were diagnosed with diabetes mellitus in their mid-twenties, and both had optic atrophy. The older brother had minor ataxia, the younger brother did not have any neurological symptoms. AVP deficiency (formerly known as diabetes insipidus) was excluded in the older brother. The younger brother was using desmopressin because of nocturia. There were no other signs of endocrinological or urological problems in both patients. Auto-immune diabetes mellitus, MODY and MIDD were excluded. Both brothers were found to be homozygous for the pathogenic variant c.1672C &gt; T p. Arg558Cys in exon 8 of the WFS1 gene. This is a founder mutation in the Ashkenazi Jewish population. Their parents were not consanguineous. This mutation was only recently found to cause a milder phenotype than classical Wolfram syndrome due to less defective protein function.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"37 ","pages":"Article 100197"},"PeriodicalIF":0.0,"publicationDate":"2025-08-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144826990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary adrenal insufficiency presenting as rhabdomyolysis and severe hyponatremia after COVID-19 infection COVID-19感染后表现为横纹肌溶解和严重低钠血症的原发性肾上腺功能不全
Q4 Medicine Pub Date : 2025-07-30 DOI: 10.1016/j.jecr.2025.100196
Spencer Bonnerup, Elizabeth Cho, Ashton Bosler-Spencer, Adrian Singson, Margaret Beliveau-Ficalora
A 28-year-old male with no medical history except recent, untreated, COVID-19 infection presented with subjective weakness, weight loss, severe hyponatremia, rhabdomyolysis, and new diagnosis primary adrenal insufficiency; a unique clinical presentation not seen in the literature. Initial sodium was 115 mmol/L. Cortisol was undetectable. Fluid resuscitation was initiated due to hypotension and elevated creatine phosphokinase, indicative of rhabdomyolysis. Further testing demonstrated 21-hydroxylase antibodies indicating Addison's disease. Molecular mimicry has been proposed as a mechanism for the development of adrenal insufficiency after COVID-19 infection. The patient responded to steroid replacement and was stable for discharge.
28岁男性,除近期未经治疗外无其他病史,感染COVID-19,表现为主观虚弱、体重减轻、严重低钠血症、横纹肌溶解,新诊断为原发性肾上腺功能不全;文献中未见的独特临床表现。初始钠浓度为115 mmol/L。皮质醇检测不到。由于低血压和肌酸磷酸激酶升高,提示横纹肌溶解,开始进行液体复苏。进一步的检测显示21-羟化酶抗体提示Addison病。分子模仿被认为是COVID-19感染后肾上腺功能不全的一种机制。患者对类固醇替代治疗有反应,出院时病情稳定。
{"title":"Primary adrenal insufficiency presenting as rhabdomyolysis and severe hyponatremia after COVID-19 infection","authors":"Spencer Bonnerup,&nbsp;Elizabeth Cho,&nbsp;Ashton Bosler-Spencer,&nbsp;Adrian Singson,&nbsp;Margaret Beliveau-Ficalora","doi":"10.1016/j.jecr.2025.100196","DOIUrl":"10.1016/j.jecr.2025.100196","url":null,"abstract":"<div><div>A 28-year-old male with no medical history except recent, untreated, COVID-19 infection presented with subjective weakness, weight loss, severe hyponatremia, rhabdomyolysis, and new diagnosis primary adrenal insufficiency; a unique clinical presentation not seen in the literature. Initial sodium was 115 mmol/L. Cortisol was undetectable. Fluid resuscitation was initiated due to hypotension and elevated creatine phosphokinase, indicative of rhabdomyolysis. Further testing demonstrated 21-hydroxylase antibodies indicating Addison's disease. Molecular mimicry has been proposed as a mechanism for the development of adrenal insufficiency after COVID-19 infection. The patient responded to steroid replacement and was stable for discharge.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"37 ","pages":"Article 100196"},"PeriodicalIF":0.0,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144772457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Case series of wolfram syndrome in Uzbekistan 乌兹别克斯坦wolfram综合征病例系列
Q4 Medicine Pub Date : 2025-07-04 DOI: 10.1016/j.jecr.2025.100194
Sh.T. Sultanova, A.V. Alieva, Z.A. Salikhova, N.E. Ismoilova, M.A. Akhmedova
The clinical picture of Wolfram syndrome and the data of 12 patients are described. The diagnosis of Wolfram syndrome takes time, since clinical symptoms appear within several years, and the subsequence of the onset of different components of the syndrome also varies. In the description of this series of clinical cases, we tried to analyze the pattern of appearance of clinical symptoms of Wolfram syndrome. The sequence of development of the entire picture of the disease does not always coincide with the classical course of the syndrome, which complicates timely diagnosis.
本文描述了Wolfram综合征的临床表现和12例患者的资料。Wolfram综合征的诊断需要时间,因为临床症状会在几年内出现,并且该综合征的不同组成部分的发病时间也各不相同。在对这一系列临床病例的描述中,我们试图分析Wolfram综合征临床症状的表现模式。整个疾病的发展顺序并不总是与综合征的经典病程一致,这使及时诊断变得复杂。
{"title":"Case series of wolfram syndrome in Uzbekistan","authors":"Sh.T. Sultanova,&nbsp;A.V. Alieva,&nbsp;Z.A. Salikhova,&nbsp;N.E. Ismoilova,&nbsp;M.A. Akhmedova","doi":"10.1016/j.jecr.2025.100194","DOIUrl":"10.1016/j.jecr.2025.100194","url":null,"abstract":"<div><div>The clinical picture of Wolfram syndrome and the data of 12 patients are described. The diagnosis of Wolfram syndrome takes time, since clinical symptoms appear within several years, and the subsequence of the onset of different components of the syndrome also varies. In the description of this series of clinical cases, we tried to analyze the pattern of appearance of clinical symptoms of Wolfram syndrome. The sequence of development of the entire picture of the disease does not always coincide with the classical course of the syndrome, which complicates timely diagnosis.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"37 ","pages":"Article 100194"},"PeriodicalIF":0.0,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144563172","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
“Amiodarone-Induced Grave's Disease: development of the full Grave's spectrum following amiodarone therapy” 胺碘酮诱发的格雷夫斯病:胺碘酮治疗后格雷夫斯病全谱的发展
Q4 Medicine Pub Date : 2025-07-03 DOI: 10.1016/j.jecr.2025.100195
Taylor Chayse Wilson , Louis Charles Haenel

Background

Amiodarone, a medication commonly used for management of cardiac arrythmias, is known for its multitude of side effects notoriously affecting the thyroid gland. Amiodarone creating thyroid gland dysfunction such as hypothyroidism and amiodarone induced thyrotoxicosis (AIT) types I and II has been well described; however, the development of the full Grave's spectrum including primary gland autoimmune stimulation with ophthalmopathy and pretibial myxedema has not been previously reported.

Case presentation

In this report, we describe a 77-year-old male with no personal or family history of thyroid or autoimmune disease with atrial fibrillation managed with amiodarone for several years that presented to his primary care office with ptosis and lower extremity swelling and erythema. A diagnosis of Grave's Disease was confirmed with elevated levels of thyroid stimulating immunoglobulins 87.5 Iu/L (reference: 0.00–0.55 Iu/L), TSH <0.001 Iu/mL (reference: 0.5–5.0 Iu/L), and free T4 level 1.73 ng/dL (reference: 0.58–1.64 ng/dL). Further evaluation revealed bilateral proptosis, periorbital edema, 20 pound weight loss, and bilateral lower extremity swelling and erythema attributed to pretibial myxedema all of which improved with methimazole, selenium, prednisone, and teprotumumab.

Discussion

While AIT Types I and II are characterized by the development of thyrotoxicosis, the ocular manifestations and pretibial myxedema seen with Grave's Disease are not present. Amiodarone has been shown to increase the number of la-positive T cells which have also been found to be increased in patients with thyrotoxicosis secondary to Grave Disease.

Conclusion

This case highlights a potential relationship between amiodarone and development of fulminant Grave's Disease which has not been previously described.
达碘酮是一种通常用于治疗心律失常的药物,因其影响甲状腺的众多副作用而闻名。胺碘酮引起甲状腺功能障碍,如甲状腺功能减退和胺碘酮引起的甲状腺毒症(AIT) I型和II型已被很好地描述;然而,包括原发性腺体自身免疫刺激伴眼病和胫前黏液水肿在内的整个格雷夫氏谱的发展尚未见报道。在这个报告中,我们描述了一个77岁的男性,没有个人或家族史的甲状腺或自身免疫性疾病与心房颤动治疗胺碘酮数年,提出了他的初级保健办公室与上睑下垂和下肢肿胀和红斑。甲状腺促甲状腺免疫球蛋白87.5 Iu/L(参考值:0.00-0.55 Iu/L), TSH <升高0.001 Iu/mL(参考值:0.5-5.0 Iu/L),游离T4水平升高1.73 ng/dL(参考值:0.58-1.64 ng/dL),确诊为graves病。进一步的评估显示双侧突出,眶周水肿,体重减轻20磅,双侧下肢肿胀和红斑归因于胫骨前黏液水肿,所有这些都在甲巯咪唑、硒、强的松和teprotumumab的治疗下得到改善。虽然AIT I型和II型的特点是发展为甲状腺毒症,但不存在格雷夫斯病的眼部表现和胫前粘液水肿。胺碘酮已被证明可增加la阳性T细胞的数量,在严重疾病继发甲状腺毒症患者中也发现这种细胞数量增加。结论本病例强调了胺碘酮与暴发性graves病的发展之间的潜在关系,这在以前没有被描述过。
{"title":"“Amiodarone-Induced Grave's Disease: development of the full Grave's spectrum following amiodarone therapy”","authors":"Taylor Chayse Wilson ,&nbsp;Louis Charles Haenel","doi":"10.1016/j.jecr.2025.100195","DOIUrl":"10.1016/j.jecr.2025.100195","url":null,"abstract":"<div><h3>Background</h3><div>Amiodarone, a medication commonly used for management of cardiac arrythmias, is known for its multitude of side effects notoriously affecting the thyroid gland. Amiodarone creating thyroid gland dysfunction such as hypothyroidism and amiodarone induced thyrotoxicosis (AIT) types I and II has been well described; however, the development of the full Grave's spectrum including primary gland autoimmune stimulation with ophthalmopathy and pretibial myxedema has not been previously reported.</div></div><div><h3>Case presentation</h3><div>In this report, we describe a 77-year-old male with no personal or family history of thyroid or autoimmune disease with atrial fibrillation managed with amiodarone for several years that presented to his primary care office with ptosis and lower extremity swelling and erythema. A diagnosis of Grave's Disease was confirmed with elevated levels of thyroid stimulating immunoglobulins 87.5 Iu/L (reference: 0.00–0.55 Iu/L), TSH &lt;0.001 Iu/mL (reference: 0.5–5.0 Iu/L), and free T4 level 1.73 ng/dL (reference: 0.58–1.64 ng/dL). Further evaluation revealed bilateral proptosis, periorbital edema, 20 pound weight loss, and bilateral lower extremity swelling and erythema attributed to pretibial myxedema all of which improved with methimazole, selenium, prednisone, and teprotumumab.</div></div><div><h3>Discussion</h3><div>While AIT Types I and II are characterized by the development of thyrotoxicosis, the ocular manifestations and pretibial myxedema seen with Grave's Disease are not present. Amiodarone has been shown to increase the number of la-positive T cells which have also been found to be increased in patients with thyrotoxicosis secondary to Grave Disease.</div></div><div><h3>Conclusion</h3><div>This case highlights a potential relationship between amiodarone and development of fulminant Grave's Disease which has not been previously described.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"37 ","pages":"Article 100195"},"PeriodicalIF":0.0,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144572405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erratum regarding Missing Patient Consent statements in previously published articles 关于先前发表的文章中缺少患者同意声明的勘误
Q4 Medicine Pub Date : 2025-06-01 DOI: 10.1016/j.jecr.2025.100185
{"title":"Erratum regarding Missing Patient Consent statements in previously published articles","authors":"","doi":"10.1016/j.jecr.2025.100185","DOIUrl":"10.1016/j.jecr.2025.100185","url":null,"abstract":"","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"36 ","pages":"Article 100185"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144189907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Denosumab in the treatment of delayed hypercalcemia after rhabdomyolysis Denosumab治疗横纹肌溶解后迟发性高钙血症
Q4 Medicine Pub Date : 2025-05-24 DOI: 10.1016/j.jecr.2025.100193
Nabil W.G. Sweis , Ahmed Noor , Karen Jong , Joseph L. Zapater

Background/objective

Rhabdomyolysis-associated hypercalcemia has limited management options in oliguric patients. Our objective is to describe a case of refractory rhabdomyolysis-associated hypercalcemia with concomitant anuria that was treated with denosumab.

Case presentation

A 57-year-old woman with hypertension, hyperlipidemia, and rheumatic heart disease, presented with four days of fever, chills, and right upper quadrant pain. Home medications included simvastatin and warfarin. Initial workup was notable for pyelonephritis and Escherichia coli bacteremia, and she was admitted for urosepsis. Her course was complicated by acute kidney injury requiring continuous renal replacement therapy and new-onset atrial fibrillation managed with amiodarone. During recovery, she developed rhabdomyolysis and concurrent anuria managed with intermittent hemodialysis. As rhabdomyolysis resolved, she developed hypercalcemia with a corrected calcium of 16.4 mg/dL (range, 8.6–10.6 mg/dL). Labs also showed a parathyroid hormone (PTH) level of 62 pg/mL (range, 12–88 pg/mL), and a phosphorus of 6.0 mg/dL (range, 2.5–4.5 mg/dL). Malignancy workup was unremarkable. She received four doses of calcitonin alongside cinacalcet without improvement. Daily hemodialysis was then performed with transient calcium improvements. Ultimately, she received denosumab 60 mg with normalization of serum calcium within a week.

Discussion

Severe hypercalcemia during recovery from rhabdomyolysis is challenging to manage in patients who are oliguric and/or anuric and may require denosumab for urgent normalization of the serum calcium level.

Conclusion

Denosumab may be an effective option for rhabdomyolysis-associated hypercalcemia in patients with renal impairment who do not respond to dialysis and may not tolerate bisphosphonates.
背景/目的在少尿患者中,脂肪溶解相关的高钙血症的治疗选择有限。我们的目的是描述一个难治性横纹肌溶解相关高钙血症合并无尿的病例,用地诺单抗治疗。病例表现:一名57岁女性,患有高血压、高脂血症和风湿性心脏病,表现为发热、发冷和右上腹疼痛4天。家庭用药包括辛伐他汀和华法林。初步检查发现肾盂肾炎和大肠杆菌血症,并因尿脓毒症入院。她的病程因急性肾损伤而复杂化,需要持续的肾脏替代治疗和新发心房颤动治疗胺碘酮。在康复期间,她出现横纹肌溶解和并发无尿,并接受间歇性血液透析治疗。横纹肌溶解消退后,患者出现高钙血症,校正后的钙含量为16.4 mg/dL(范围8.6-10.6 mg/dL)。实验室还显示甲状旁腺激素(PTH)水平为62 pg/mL(范围,12-88 pg/mL),磷为6.0 mg/dL(范围,2.5-4.5 mg/dL)。恶性检查无显著差异。她接受了四剂降钙素和cinacalcet治疗,但没有好转。然后进行每日血液透析,短暂的钙改善。最终,她接受了denosumab 60mg治疗,一周内血清钙恢复正常。对于少尿和/或无尿的患者,在横纹肌溶解恢复期间的严重高钙血症是具有挑战性的,可能需要地诺单抗来紧急恢复血清钙水平。结论denosumab可能是治疗无透析反应且不能耐受双膦酸盐的肾损害患者横纹肌溶解相关高钙血症的有效选择。
{"title":"Denosumab in the treatment of delayed hypercalcemia after rhabdomyolysis","authors":"Nabil W.G. Sweis ,&nbsp;Ahmed Noor ,&nbsp;Karen Jong ,&nbsp;Joseph L. Zapater","doi":"10.1016/j.jecr.2025.100193","DOIUrl":"10.1016/j.jecr.2025.100193","url":null,"abstract":"<div><h3>Background<strong>/</strong>objective</h3><div>Rhabdomyolysis-associated hypercalcemia has limited management options in oliguric patients. Our objective is to describe a case of refractory rhabdomyolysis-associated hypercalcemia with concomitant anuria that was treated with denosumab.</div></div><div><h3>Case presentation</h3><div>A 57-year-old woman with hypertension, hyperlipidemia, and rheumatic heart disease, presented with four days of fever, chills, and right upper quadrant pain. Home medications included simvastatin and warfarin. Initial workup was notable for pyelonephritis and <em>Escherichia coli</em> bacteremia, and she was admitted for urosepsis. Her course was complicated by acute kidney injury requiring continuous renal replacement therapy and new-onset atrial fibrillation managed with amiodarone. During recovery, she developed rhabdomyolysis and concurrent anuria managed with intermittent hemodialysis. As rhabdomyolysis resolved, she developed hypercalcemia with a corrected calcium of 16.4 mg/dL (range, 8.6–10.6 mg/dL). Labs also showed a parathyroid hormone (PTH) level of 62 pg/mL (range, 12–88 pg/mL), and a phosphorus of 6.0 mg/dL (range, 2.5–4.5 mg/dL). Malignancy workup was unremarkable. She received four doses of calcitonin alongside cinacalcet without improvement. Daily hemodialysis was then performed with transient calcium improvements. Ultimately, she received denosumab 60 mg with normalization of serum calcium within a week.</div></div><div><h3>Discussion</h3><div>Severe hypercalcemia during recovery from rhabdomyolysis is challenging to manage in patients who are oliguric and/or anuric and may require denosumab for urgent normalization of the serum calcium level.</div></div><div><h3>Conclusion</h3><div>Denosumab may be an effective option for rhabdomyolysis-associated hypercalcemia in patients with renal impairment who do not respond to dialysis and may not tolerate bisphosphonates.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"37 ","pages":"Article 100193"},"PeriodicalIF":0.0,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144170751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neonatal Graves’ disease from high maternal TRAB antibody levels despite definitive therapy 新生儿Graves病由高母体TRAB抗体水平引起,尽管有明确的治疗
Q4 Medicine Pub Date : 2025-05-03 DOI: 10.1016/j.jecr.2025.100192
Dalal S. Ali , Maisa H. Al Kiyumi , Abdulrahman Almoulia , Rachel K. Crowley , Medina Mohamed

Background

Graves’ disease is an autoimmune thyroid disorder that poses significant risks during pregnancy, affecting both the mother and fetus.

Case presentation

We present four cases of neonatal Graves' disease arising in the offspring of two women treated for Graves' disease, highlighting the disease's transient but potentially severe impact on newborns. In the first case, the pregnant woman underwent a total thyroidectomy during the second trimester, whereas in the second case, the patient had Graves' disease and was treated with radioactive iodine six years prior. Both women demonstrated a very high level of thyrotropin receptor antibodies (TRAb) during pregnancy.

Discussion

These cases underline the necessity of vigilant monitoring of TRAb levels in pregnant women with a history of Graves' disease, regardless of previous treatment or current euthyroid status. This approach aims to facilitate early detection and treatment of neonatal Graves’ disease, mitigating its impact on growth and development.

Conclusion

Our findings support recommendations for baseline and mid-gestation TRAb testing in this population, as well as immediate postnatal testing for neonates born to mothers with active or inactive Graves’ disease.
格雷夫斯病是一种自身免疫性甲状腺疾病,在怀孕期间对母亲和胎儿都有重大风险。病例介绍:我们报告了两名接受格雷夫斯病治疗的妇女的后代中出现的4例新生儿格雷夫斯病,强调了这种疾病对新生儿的短暂但潜在的严重影响。在第一个病例中,孕妇在妊娠中期接受了甲状腺全切除术,而在第二个病例中,患者患有格雷夫斯病,并在六年前接受了放射性碘治疗。这两名妇女在怀孕期间都表现出非常高水平的促甲状腺激素受体抗体(TRAb)。这些病例强调有Graves病史的孕妇警惕监测TRAb水平的必要性,无论既往治疗或目前甲状腺功能正常。该方法旨在促进新生儿Graves病的早期发现和治疗,减轻其对生长发育的影响。结论:我们的研究结果支持在这一人群中进行基线和妊娠中期TRAb检测的建议,以及对患有活动性或非活动性Graves病的母亲所生的新生儿进行产后立即检测。
{"title":"Neonatal Graves’ disease from high maternal TRAB antibody levels despite definitive therapy","authors":"Dalal S. Ali ,&nbsp;Maisa H. Al Kiyumi ,&nbsp;Abdulrahman Almoulia ,&nbsp;Rachel K. Crowley ,&nbsp;Medina Mohamed","doi":"10.1016/j.jecr.2025.100192","DOIUrl":"10.1016/j.jecr.2025.100192","url":null,"abstract":"<div><h3>Background</h3><div>Graves’ disease is an autoimmune thyroid disorder that poses significant risks during pregnancy, affecting both the mother and fetus.</div></div><div><h3>Case presentation</h3><div>We present four cases of neonatal Graves' disease arising in the offspring of two women treated for Graves' disease, highlighting the disease's transient but potentially severe impact on newborns. In the first case, the pregnant woman underwent a total thyroidectomy during the second trimester, whereas in the second case, the patient had Graves' disease and was treated with radioactive iodine six years prior. Both women demonstrated a very high level of thyrotropin receptor antibodies (TRAb) during pregnancy.</div></div><div><h3>Discussion</h3><div>These cases underline the necessity of vigilant monitoring of TRAb levels in pregnant women with a history of Graves' disease, regardless of previous treatment or current euthyroid status. This approach aims to facilitate early detection and treatment of neonatal Graves’ disease, mitigating its impact on growth and development.</div></div><div><h3>Conclusion</h3><div>Our findings support recommendations for baseline and mid-gestation TRAb testing in this population, as well as immediate postnatal testing for neonates born to mothers with active or inactive Graves’ disease.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"36 ","pages":"Article 100192"},"PeriodicalIF":0.0,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143931886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Iatrogenic neuroleptic malignant syndrome revealing primary hyperthyroidism with thyrotoxic heart disease: A case report 医源性抗精神病药恶性综合征显示原发性甲状腺功能亢进伴甲状腺毒性心脏病1例
Q4 Medicine Pub Date : 2025-04-25 DOI: 10.1016/j.jecr.2025.100191
Wendlassida Martin Nacanabo , Yannick Laurent Tchenadoyo Bayala , Abdoul Djalidou Traoré , Arsène Aimé Yameogo , Yempabou Sagna , Abraham Hermann Wend Pagnande Bagabila , Carole Gilberte Kyelem , Téné Marceline Yaméogo , Macaire Sampawendé Ouedraogo

Introduction

Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening complication of antipsychotic medication, while hyperthyroidism is known to affect multiple organ systems, particularly the cardiovascular system. The concomitant occurrence of these conditions presents rare diagnostic and management challenges.

Case presentation

We report a case of a 75-year-old female with hypertension who had been on neuroleptic therapy (Haloperidol, Promethazine) for depression for four months. She presented with altered general condition, hyperthermia (40.8 °C), altered consciousness, hypersialorrhea, aphasia, resting tremor, signs of thyrotoxicosis including exophthalmos and goiter, and global cardiac insufficiency. Laboratory investigations revealed severely suppressed TSH (0.001 mIU/L), markedly elevated FT4 (78 ng/L) and FT3 (20 ng/L), and bi-cytopenia. Imaging confirmed a hypervascularized diffuse goiter and echocardiography demonstrated hyperkinesia with elevated left ventricular ejection fraction (75 %). The patient was diagnosed with primary hyperthyroidism complicated by thyrotoxic heart disease, revealed by neuroleptic malignant syndrome. Management included immediate discontinuation of neuroleptics, initiation of antithyroid medication (Thiamazole), beta-blockade (Propranolol), and heart failure therapy. Complete resolution of symptoms was achieved within two weeks.

Conclusion

This case highlights the importance of considering hyperthyroidism in the differential diagnosis of patients presenting with NMS, particularly when cardiovascular manifestations are prominent.
神经安定药恶性综合征(NMS)是一种罕见但危及生命的抗精神病药物并发症,而甲亢已知影响多器官系统,特别是心血管系统。这些情况的同时发生提出了罕见的诊断和管理挑战。我们报告一例75岁女性高血压患者,因抑郁症而服用抗精神病药物(氟哌啶醇、异丙嗪)4个月。患者表现为全身状况改变、高热(40.8°C)、意识改变、多涎、失语、静息性震颤、甲状腺毒症症状包括眼球突出、甲状腺肿和全心功能不全。实验室调查显示严重抑制TSH (0.001 mIU/L), FT4 (78 ng/L)和FT3 (20 ng/L)显著升高,双细胞减少。影像学证实血管充血性弥漫性甲状腺肿,超声心动图显示运动亢进伴左心室射血分数升高(75%)。患者诊断为原发性甲状腺功能亢进并甲状腺毒性心脏病,表现为抗精神病药恶性综合征。治疗包括立即停用抗精神病药物,开始抗甲状腺药物(噻马唑),β -阻断剂(心得安)和心力衰竭治疗。症状在两周内得到完全解决。结论本病例强调了在NMS患者鉴别诊断中考虑甲状腺功能亢进的重要性,特别是当心血管表现突出时。
{"title":"Iatrogenic neuroleptic malignant syndrome revealing primary hyperthyroidism with thyrotoxic heart disease: A case report","authors":"Wendlassida Martin Nacanabo ,&nbsp;Yannick Laurent Tchenadoyo Bayala ,&nbsp;Abdoul Djalidou Traoré ,&nbsp;Arsène Aimé Yameogo ,&nbsp;Yempabou Sagna ,&nbsp;Abraham Hermann Wend Pagnande Bagabila ,&nbsp;Carole Gilberte Kyelem ,&nbsp;Téné Marceline Yaméogo ,&nbsp;Macaire Sampawendé Ouedraogo","doi":"10.1016/j.jecr.2025.100191","DOIUrl":"10.1016/j.jecr.2025.100191","url":null,"abstract":"<div><h3>Introduction</h3><div>Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening complication of antipsychotic medication, while hyperthyroidism is known to affect multiple organ systems, particularly the cardiovascular system. The concomitant occurrence of these conditions presents rare diagnostic and management challenges.</div></div><div><h3>Case presentation</h3><div>We report a case of a 75-year-old female with hypertension who had been on neuroleptic therapy (Haloperidol, Promethazine) for depression for four months. She presented with altered general condition, hyperthermia (40.8 °C), altered consciousness, hypersialorrhea, aphasia, resting tremor, signs of thyrotoxicosis including exophthalmos and goiter, and global cardiac insufficiency. Laboratory investigations revealed severely suppressed TSH (0.001 mIU/L), markedly elevated FT4 (78 ng/L) and FT3 (20 ng/L), and bi-cytopenia. Imaging confirmed a hypervascularized diffuse goiter and echocardiography demonstrated hyperkinesia with elevated left ventricular ejection fraction (75 %). The patient was diagnosed with primary hyperthyroidism complicated by thyrotoxic heart disease, revealed by neuroleptic malignant syndrome. Management included immediate discontinuation of neuroleptics, initiation of antithyroid medication (Thiamazole), beta-blockade (Propranolol), and heart failure therapy. Complete resolution of symptoms was achieved within two weeks.</div></div><div><h3>Conclusion</h3><div>This case highlights the importance of considering hyperthyroidism in the differential diagnosis of patients presenting with NMS, particularly when cardiovascular manifestations are prominent.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"36 ","pages":"Article 100191"},"PeriodicalIF":0.0,"publicationDate":"2025-04-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144069624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rebound ketoacidosis in a patient with diabetic ketoacidosis using ultra-long-acting insulin 超长效胰岛素治疗糖尿病酮症酸中毒患者的反跳性酮症酸中毒
Q4 Medicine Pub Date : 2025-04-24 DOI: 10.1016/j.jecr.2025.100190
Hsin-I Chi , Ye-Fong Du

Background/objective

A 26-year-old Taiwanese woman with type 1 diabetes mellitus developed diabetic ketoacidosis after missing a premixed insulin dose. The case is notable for recurrent ketosis and hyperglycemia despite a 6-h overlap during the transition from intravenous to subcutaneous insulin therapy. The objective of this report is to describe the challenges of transitioning insulin regimens with ultra-long-acting insulin.

Case presentation

A 26-year-old woman presented with severe diabetic ketoacidosis, confirmed by laboratory findings of blood glucose at 520 mg/dL, pH 7.14, bicarbonate 8 mmol/L, and serum ketones 5.9 mmol/L. She received intravenous insulin for 48 hours before transitioning to subcutaneous IGlar-300 with a 6-h overlap. Despite initial improvement, ketones rebounded to 4.2 mmol/L with hyperglycemia 7 hours after intravenous insulin discontinuation. Reintroduction of intravenous insulin for 48 hours and subsequent doses of IGlar-300 stabilized her condition, allowing discharge with resolved ketosis and improved glycemic control.

Discussion

This case underscores the challenges of transitioning to ultra-long-acting insulin during management of diabetic ketoacidosis. The pharmacokinetics of basal insulin analogs like IGlar-300 may necessitate extended overlap with intravenous insulin to maintain stable glycemic control and prevent rebound ketosis.

Conclusion

This case highlights the need for careful management during the transition from intravenous to subcutaneous ultra-long-acting insulin to prevent rebound ketosis. Although not specifically addressed in current guidelines, an extended overlap with intravenous insulin may be required in similar cases.

Clinical Relevance

This case underscores the importance of tailored DKA management when using ultra-long-acting insulins, highlighting the need for extended overlap durations to ensure ketone clearance and avoid rebound ketoacidosis.
背景/目的一名26岁台湾女性1型糖尿病患者在错过预混合胰岛素剂量后发生糖尿病酮症酸中毒。该病例值得注意的是,尽管在从静脉注射到皮下胰岛素治疗的过渡期间有6小时重叠,但仍有复发性酮症和高血糖。本报告的目的是描述用超长效胰岛素过渡胰岛素治疗方案的挑战。病例介绍:一名26岁女性,因严重的糖尿病酮症酸中毒,经实验室检查证实:血糖520 mg/dL, pH值7.14,碳酸氢盐8 mmol/L,血清酮5.9 mmol/L。她接受了48小时的静脉注射胰岛素,然后过渡到皮下注射IGlar-300,重叠6小时。尽管最初有所改善,但在静脉注射胰岛素停药7小时后,酮类反弹至4.2 mmol/L并出现高血糖。再次静脉注射胰岛素48小时,随后服用IGlar-300,病情稳定,出院时酮症得到缓解,血糖控制得到改善。本病例强调了在糖尿病酮症酸中毒治疗中过渡到超长效胰岛素的挑战。基础胰岛素类似物如IGlar-300的药代动力学可能需要与静脉注射胰岛素延长重叠,以维持稳定的血糖控制和防止反弹酮症。结论该病例强调了超长效胰岛素从静脉注射到皮下注射的过渡过程中需要谨慎管理,以防止反弹酮症。虽然目前的指南中没有特别提到,但在类似病例中可能需要与静脉注射胰岛素扩大重叠。该病例强调了在使用超长效胰岛素时量身定制DKA管理的重要性,强调了延长重叠持续时间以确保酮清除和避免反弹酮症酸中毒的必要性。
{"title":"Rebound ketoacidosis in a patient with diabetic ketoacidosis using ultra-long-acting insulin","authors":"Hsin-I Chi ,&nbsp;Ye-Fong Du","doi":"10.1016/j.jecr.2025.100190","DOIUrl":"10.1016/j.jecr.2025.100190","url":null,"abstract":"<div><h3>Background/objective</h3><div>A 26-year-old Taiwanese woman with type 1 diabetes mellitus developed diabetic ketoacidosis after missing a premixed insulin dose. The case is notable for recurrent ketosis and hyperglycemia despite a 6-h overlap during the transition from intravenous to subcutaneous insulin therapy. The objective of this report is to describe the challenges of transitioning insulin regimens with ultra-long-acting insulin.</div></div><div><h3>Case presentation</h3><div>A 26-year-old woman presented with severe diabetic ketoacidosis, confirmed by laboratory findings of blood glucose at 520 mg/dL, pH 7.14, bicarbonate 8 mmol/L, and serum ketones 5.9 mmol/L. She received intravenous insulin for 48 hours before transitioning to subcutaneous IGlar-300 with a 6-h overlap. Despite initial improvement, ketones rebounded to 4.2 mmol/L with hyperglycemia 7 hours after intravenous insulin discontinuation. Reintroduction of intravenous insulin for 48 hours and subsequent doses of IGlar-300 stabilized her condition, allowing discharge with resolved ketosis and improved glycemic control.</div></div><div><h3>Discussion</h3><div>This case underscores the challenges of transitioning to ultra-long-acting insulin during management of diabetic ketoacidosis. The pharmacokinetics of basal insulin analogs like IGlar-300 may necessitate extended overlap with intravenous insulin to maintain stable glycemic control and prevent rebound ketosis.</div></div><div><h3>Conclusion</h3><div>This case highlights the need for careful management during the transition from intravenous to subcutaneous ultra-long-acting insulin to prevent rebound ketosis. Although not specifically addressed in current guidelines, an extended overlap with intravenous insulin may be required in similar cases.</div></div><div><h3>Clinical Relevance</h3><div>This case underscores the importance of tailored DKA management when using <strong>ultra-long-acting insulins</strong>, highlighting the need for <strong>extended overlap durations</strong> to ensure ketone clearance and avoid rebound ketoacidosis.</div></div>","PeriodicalId":56186,"journal":{"name":"Journal of Clinical and Translational Endocrinology: Case Reports","volume":"36 ","pages":"Article 100190"},"PeriodicalIF":0.0,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143912262","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Clinical and Translational Endocrinology: Case Reports
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1